Provided by Tiger Fintech (Singapore) Pte. Ltd.

Perspective Therapeutics

3.89
+0.21005.71%
Volume:422.00K
Turnover:1.60M
Market Cap:288.75M
PE:-3.20
High:3.91
Open:3.74
Low:3.65
Close:3.68
Loading ...

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

GlobeNewswire
·
25 Jul

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

GlobeNewswire
·
15 Jul

Perspective Therapeutics (CATX) Receives a Buy from Scotiabank

TIPRANKS
·
10 Jul

Perspective Therapeutics management to meet with Piper Sandler

TIPRANKS
·
02 Jul

Buy Rating for Perspective Therapeutics: Clinical Advancements and Strategic Developments Drive Positive Outlook

TIPRANKS
·
25 Jun

Perspective Therapeutics Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
23 Jun

B. Riley Raises Price Target on Perspective Therapeutics to $12 From $9, Keeps Buy Rating

MT Newswires Live
·
23 Jun

Optimistic Buy Rating for Perspective Therapeutics Driven by Strategic Developments and Promising Clinical Data

TIPRANKS
·
23 Jun

Perspective Therapeutics commences recruitment for 212PbVMT-alpha-NET

TIPRANKS
·
23 Jun

LifeSci Capital Sticks to Their Buy Rating for Perspective Therapeutics (CATX)

TIPRANKS
·
07 Jun

Perspective Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
03 Jun

RBC Raises Price Target on Perspective Therapeutics to $16 From $15, Keeps Outperform, Speculative Risk

MT Newswires Live
·
03 Jun

Promising Clinical Updates and Strong Safety Profile Support Buy Rating for Perspective Therapeutics

TIPRANKS
·
02 Jun

Perspective Therapeutics (CATX) Gets a Buy from Truist Financial

TIPRANKS
·
02 Jun

Bank of America Securities Reaffirms Their Hold Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
01 Jun

Perspective Therapeutics Reports Promising Trial Results for [212Pb]VMT-α-NET

TIPRANKS
·
31 May

Perspective Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
29 May

Buy Rating on Perspective Therapeutics: Promising Clinical Data, Strategic Advancements, and Strong Financial Position

TIPRANKS
·
27 May

Perspective Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
15 May

Truist Securities Adjusts Perspective Therapeutics Price Target to $8 From $10, Maintains Buy Rating

MT Newswires Live
·
14 May